Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 5:57 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1537–1560 of 1,904 matching trials from the live ClinicalTrials.gov search.

Filters: Sponsor: AstraZeneca Clear all

Conditions: Chronic Heart Failure With Reduced Ejection Fraction (HFrEF)
Interventions: Dapagliflozin, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 4,744 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 86
States / cities: Fairhope, Alabama • Mobile, Alabama • Sheffield, Alabama + 74 more

Conditions: Type 2 Diabetes Mellitus
Interventions: 2.5 mg Saxagliptin tablet, 5 mg dapagliflozin / 1000 mg metformin XR tablet, Triple FCDP - 2.5 mg saxagliptin / 5 mg dapagliflozin / 1000 mg metformin XR, 5 mg saxagliptin, 10 mg dapagliflozin / 1000 mg metformin XR tablet, Triple FCDP - 5 mg saxagliptin / 10 mg dapagliflozin / 1000 mg metformin XR; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 85 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: GERD
Interventions: Antacids; Drug
Lead sponsor: Digestive & Liver Disease Specialists; Other
Eligibility: 18 Years to 80 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Norfolk, Virginia

Conditions: Zollinger-Ellison Syndrome
Interventions: Esomeprazole magnesium (Nexium); Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 5
States / cities: Los Angeles, California • Gainesville, Florida • Columbus, Ohio + 2 more

Conditions: Healthy
Interventions: ABT-143, ABT-335, rosuvastatin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2008
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Advanced Ovarian Cancer
Interventions: Bevacizumab, Durvalumab, Olaparib, Placebo olaparib, Durvalumab placebo, Carboplatin+Paclitaxel; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years · Female only
Enrollment: 1,407 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 26
States / cities: Foothill Ranch, California • Los Angeles, California • Orange, California + 22 more

Conditions: Type 2 Diabetes Mellitus
Interventions: Dapagliflozin, Metformin XR, dapagliflozin matching Placebo, metformin HCl Modified Release matching Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 77 Years
Enrollment: 1,093 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 64
States / cities: Ozark, Alabama • Tempe, Arizona • Concord, California + 53 more

Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions: Acalabrutinib, Obinutuzumab; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 8
States / cities: Basking Ridge, New Jersey • Hackensack, New Jersey • Middletown, New Jersey + 5 more

Conditions: Healthy Volunteers, Patients, Pharmacokinetics, Renal Impairment
Interventions: TC-5214; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 2
States / cities: Orlando, Florida • Minneapolis, Minnesota

Conditions: Advanced Prostate Adenocarcinoma
Interventions: AZD2171; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 3
States / cities: San Francisco, California • Chicago, Illinois • Nashville, Tennessee

Conditions: Healthy Participants
Interventions: AZD4144 Part A, AZD4144 Part B, Placebo Part A, Placebo Part B; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 95 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 2
States / cities: Glendale, California • Brooklyn, Maryland

Conditions: BRCA1 Gene Mutation, BRCA2 Gene Mutation, Ovarian Serous Adenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
Interventions: Durvalumab, Laboratory Biomarker Analysis, Olaparib, Tremelimumab; Biological · Other · Drug
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older · Female only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 2
States / cities: Buffalo, New York • New York, New York

Conditions: Type 2 Diabetes
Interventions: exenatide once weekly, exenatide once monthly suspension; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 2
States / cities: Phoenix, Arizona • Lincoln, Nebraska

Conditions: Chronic Kidney Disease
Interventions: AZD5718, Dapagliflozin 10 mg, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 613 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 22
States / cities: Canoga Park, California • La Mesa, California • San Carlos, California + 19 more

Conditions: Anemia
Interventions: Roxadustat, Epoetin alfa; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 2,133 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 51
States / cities: Huntsville, Alabama • El Centro, California • Fairfield, California + 41 more

Conditions: Malignant Neoplastic Disease (Disorder)
Interventions: Saruparib, FoundationOne®CDx; Drug · Diagnostic Test
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Multiple Myeloma, Multiple Chronic Conditions
Interventions: Patient-reported outcome measure, Comprehensive Medication Review, Pharmacist communication; Other
Lead sponsor: University of Tennessee; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Hormone-Sensitive Prostate Cancer
Interventions: Capivasertib, Placebo, Abiraterone Acetate; Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years · Male only
Enrollment: 1,012 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 33
States / cities: Tucson, Arizona • La Jolla, California • Orange, California + 29 more

Conditions: Acute Coronary Syndromes
Interventions: Non-Interventional Study; Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 55
States / cities: Birmingham, Alabama • Mobile, Alabama • Little Rock, Arkansas + 45 more

Conditions: Asthma
Interventions: AZD7594 DPI 55μg/50μg., AZD7594 DPI 99 µg/90 µg, AZD7594 DPI 198 µg/180 µg, AZD7594 DPI 396 µg/360 µg once daily., AZD7594 DPI 792 µg/720 µg, Placebo for AZD7594 once daily., FF 100 µg once daily (open-label); Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 808 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 21
States / cities: Sheffield, Alabama • Phoenix, Arizona • Fullerton, California + 18 more

Conditions: Coronary Heart Disease (CHD)
Interventions: MEDI6570, Placebo; Biological
Lead sponsor: AstraZeneca; Industry
Eligibility: 21 Years and older
Enrollment: 423 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 19
States / cities: Mobile, Alabama • Beverly Hills, California • Covina, California + 15 more

Conditions: Endometrial Cancer
Interventions: Trastuzumab Deruxtecan, Chemotherapy; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 710 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 14
States / cities: Fort Lauderdale, Florida • Miami, Florida • Miami Beach, Florida + 10 more

Conditions: Metastatic Castration-Resistant Prostate Cancer
Interventions: AZD2287, AZD2275, AZD2284; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 12
States / cities: Palo Alto, California • San Diego, California • Miami, Florida + 9 more

Conditions: Hypereosinophilic Syndrome (HES)
Interventions: no intervention; Other
Lead sponsor: AstraZeneca; Industry
Eligibility: Not listed
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Cambridge, Massachusetts

Search by objective public record fields.

Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure

A Study to Evaluate the Food Effect on Drug Availability, Pharmacokinetic (PK) Properties, Safety and Tolerability of Two Different Dose Combination Therapy of Saxagliptin/Dapagliflozin/Metformin Extended-release (XR) Against Individual Component Co-administration.

Nexium 40mg Once Daily vs Prevacid 30mg Twice a Day for Control of Severe GERD

Esomeprazole In Patients With Gastric Acid Hypersecretory States Including Idiopathic Hypersecretion and Zollinger-Ellison Syndrome

Comparison of the Bioavailability of Fenofibric Acid and Rosuvastatin From 5/45 mg Strength of ABT-143 Relative to That From the Coadministration of ABT-335 (Fenofibric Acid) 45 mg and Rosuvastatin Calcium 5 mg

Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients

Study of Dapagliflozin in Combination With Metformin XR to Initiate the Treatment of Type 2 Diabetes

A Study on Limiting Treatment Time With Acalabrutinib Combined With Obinutuzumab in People With CLL or SLL

To Compare the Pharmacokinetics of a Single Oral Dose of TC-5214 in Subjects With Renal Impairment and With Subjects With Normal Renal Function

Study to Assess Safety and Tolerability of AZD2171 After Multiple Doses in Patients With Advanced Prostate Cancer

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4144 Following Single and Multiple Ascending Doses Via Oral Administration to Healthy Participants

Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation

A Study to Examine the Efficacy, Safety and Tolerability, and Pharmacokinetics of Exenatide Once Monthly Suspension

A Study to Evaluate the Safety and Efficacy of AZD5718 in Participants With Proteinuric Chronic Kidney Disease

Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease, on Dialysis.

Saruparib in HRDsig+ Solid Tumors

Oral Adherence in Hematological Oncology Agents and Impact on Comorbid Therapy Adherence

Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency

Utilization of Ticagrelor in the Upstream Setting for Non-ST-Segment Elevation Myocardial Infarction (UPSTREAM): An ED-Based Clinical Registry

A Study to Assess the Efficacy and Safety of Multiple Dose Levels of AZD7594 Administered Once Daily by Inhalation in Asthmatic Subjects

Efficacy and Safety of MEDI6570 in Patients With a History of Myocardial Infarction

A Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer in Adjuvant Setting

A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer

TrinetX Study of Hypereosinophilic Syndrome (HES) Without an Identifiable Non-haematological Secondary Cause